0001493152-24-007873.txt : 20240226
0001493152-24-007873.hdr.sgml : 20240226
20240226184112
ACCESSION NUMBER: 0001493152-24-007873
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240222
FILED AS OF DATE: 20240226
DATE AS OF CHANGE: 20240226
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vaknin Rachel
CENTRAL INDEX KEY: 0001923217
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19871
FILM NUMBER: 24681097
MAIL ADDRESS:
STREET 1: DROR 3/10
CITY: ZICHRON YAAKOV
STATE: L3
ZIP: 3090216
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Microbot Medical Inc.
CENTRAL INDEX KEY: 0000883975
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 943078125
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 25 RECREATION PARK DR SUITE 108
CITY: HINGHAM
STATE: MA
ZIP: 02043
BUSINESS PHONE: 908-938-5561
MAIL ADDRESS:
STREET 1: 25 RECREATION PARK DR SUITE 108
CITY: HINGHAM
STATE: MA
ZIP: 02043
FORMER COMPANY:
FORMER CONFORMED NAME: STEMCELLS INC
DATE OF NAME CHANGE: 20000524
FORMER COMPANY:
FORMER CONFORMED NAME: CYTOTHERAPEUTICS INC/DE
DATE OF NAME CHANGE: 19930328
4
1
ownership.xml
X0508
4
2024-02-22
0
0000883975
Microbot Medical Inc.
MBOT
0001923217
Vaknin Rachel
C/O MICROBOT MEDICAL INC.
288 GROVE STREET, SUITE 388
BRAINTREE
MA
02184
0
1
0
0
Chief Financial Officer
0
Stock Option (Right to Buy)
1.2684
2024-02-22
4
A
0
17500
0
A
2034-02-22
Common Stock, par value $0.01 per share
17500
17500
D
Stock Option (Right to Buy)
1.2684
2024-02-22
4
A
0
17500
0
A
2024-02-22
2034-02-22
Common Stock, par value $0.01 per share
17500
17500
D
The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan (the "Plan"): (a) on August 22, 2024, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan.
/s/ Rachel Vaknin
2024-02-26